Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Qin Ding, Shuqi Huang, Zexu Sun, Kaifeng Chen, Xin Li & Qi Pei. (2022) A Review of Population Pharmacokinetic Models of Posaconazole. Drug Design, Development and Therapy 16, pages 3691-3709.
Read now
Read now
Daniel Echeverria-Esnal, Clara Martín-Ontiyuelo, Maria Eugenia Navarrete-Rouco, Jaime Barcelo-Vidal, David Conde-Estévez, Nuria Carballo, Marta De-Antonio Cuscó, Olivia Ferrández, Juan Pablo Horcajada & Santiago Grau. (2022) Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review. Expert Review of Anti-infective Therapy 20:2, pages 179-197.
Read now
Read now
Paraskevi Panagopoulou & Emmanuel Roilides. (2022) Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections. Expert Opinion on Pharmacotherapy 23:2, pages 175-199.
Read now
Read now
Athanasios Tragiannidis, Anastasia Gkampeta, Maria Vousvouki, Eleni Vasileiou & Andreas H. Groll. (2021) Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opinion on Drug Safety 20:9, pages 1061-1074.
Read now
Read now
Chiara Maria Dellacasa, Alessandro Busca, Ernesta Audisio, Filippo Marmont, Anna Maria Barbui, Michele Falda, Francesco Giuseppe De Rosa, Chiara Frairia, Bernardino Allione, Stefano D’Ardia, Semra Aydin, Clara Pecoraro, Sara Manetta & Umberto Vitolo. (2014) Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. Journal of Chemotherapy 26:5, pages 315-320.
Read now
Read now
Ganesh Chandra Sahoo, Md. Yousuf Ansari, Manas Ranjan Dikhit, M. Kannan, Sindhuprava Rana & Pradeep Das. (2014) Structure prediction of gBP21 protein of L. donovani and its molecular interaction. Journal of Biomolecular Structure and Dynamics 32:5, pages 709-729.
Read now
Read now
Maged Muhammed, Herman Carneiro, Jeffrey Coleman & Eleftherios Mylonakis. (2011) The challenge of managing fusariosis. Virulence 2:2, pages 91-96.
Read now
Read now
Rungmei S. K. Marak, Richa Misra, M. S. Ansari, Ajai Dixit, Poornima, K. N. Prasad & T. N. Dhole. (2010) Successful medical management of renal zygomycosis: a summary of two cases and a review of the Indian literature. Medical Mycology 48:8, pages 1088-1095.
Read now
Read now
Winter J Smith, Richard H Drew & John R Perfect. (2009) Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Review of Anti-infective Therapy 7:2, pages 165-181.
Read now
Read now
Allen Moton, Lei Ma, Gopal Krishna, Monika Martinho, Michael Seiberling & James McLeod. (2009) Effects of oral posaconazole on the pharmacokinetics of sirolimus. Current Medical Research and Opinion 25:3, pages 701-707.
Read now
Read now
Stefan Langner, Philipp B Staber & Peter Neumeister. (2008) Posaconazole in the management of refractory invasive fungal infections. Therapeutics and Clinical Risk Management 4:4, pages 747-758.
Read now
Read now
Donald G. Ahearn, Shangtong Zhang, R. Doyle Stulting, Brian L. Schwam, Robert B. Simmons, Michael A. Ward, George E. Pierce & Sidney A. Crow$suffix/text()$suffix/text(). (2008) Fusarium keratitis and contact lens wear: facts and speculations. Medical Mycology 46:5, pages 397-410.
Read now
Read now
Christine C Chiou, Thomas J Walsh & Andreas H Groll. (2007) Clinical pharmacology of antifungal agents in pediatric patients. Expert Opinion on Pharmacotherapy 8:15, pages 2465-2489.
Read now
Read now
Harrys A Torres & Roberto C Arduino. (2007) Fosamprenavir calcium plus ritonavir for HIV infection. Expert Review of Anti-infective Therapy 5:3, pages 349-363.
Read now
Read now
Douglas S Kwon & Eleftherios Mylonakis. (2007) Posaconazole: a new broad-spectrum antifungal agent. Expert Opinion on Pharmacotherapy 8:8, pages 1167-1178.
Read now
Read now
Gulsen Ozkaya Sahin & Murat Akova. (2006) Treatment of invasive infections due to rare or emerging yeasts and moulds. Expert Opinion on Pharmacotherapy 7:9, pages 1181-1190.
Read now
Read now
George Aperis & Eleftherios Mylonakis. (2006) Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opinion on Investigational Drugs 15:6, pages 579-602.
Read now
Read now
Karl V. Clemons & David A. Stevens. (2006) Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them?. Medical Mycology 44:sup1, pages 119-126.
Read now
Read now
Articles from other publishers (69)
Andreas H. Groll, Katharina Körholz, Malcolm Holterhus & Thomas Lehrnbecher. (2023) New and emerging options for management of invasive fungal diseases in paediatric patients. Mycoses 67:1.
Crossref
Crossref
Sanjeevani Deshkar, Purva Yeole, Jayashri Mahore, Ankita Shinde & Prabhanjan Giram. (2023) Polyelectrolyte-Complex-Based Hydrogel Inserts for Vaginal Delivery of Posaconazole and Probiotics. Gels 9:11, pages 851.
Crossref
Crossref
Yehia Elgammal, Ehab A Salama & Mohamed N Seleem. (2023)
Saquinavir potentiates itraconazole’s antifungal activity against multidrug-resistant
Candida auris in vitro
and
in vivo
. Medical Mycology 61:9.
Crossref
Crossref
Michail Lykouras, Malvina Orkoula & Christos Kontoyannis. (2022) Formation and Characterisation of Posaconazole Hydrate Form. Pharmaceuticals 16:1, pages 65.
Crossref
Crossref
Sakineh Dadashpour, Elham Ghobadi & Saeed Emami. (2022) Chemical and biological aspects of posaconazole as a classic antifungal agent with non-classical properties: highlighting a tetrahydrofuran-based drug toward generation of new drugs. Medicinal Chemistry Research 31:6, pages 833-850.
Crossref
Crossref
A. V. Veselov & N. N. Klimko. (2022) Intravenous posaconazole: key features of clinical pharmacology and practical applications. Oncohematology 17:2, pages 121-133.
Crossref
Crossref
Tian Zhang, Jie Bai, Mingxia Huang, Ruixiao Li, Yang Liu, Ansheng Liu & Jixin Liu. (2021) Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia. Journal of Microbiology, Immunology and Infection 54:6, pages 1139-1146.
Crossref
Crossref
Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park & Byung Soo Kim. (2020) Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. Therapeutic Advances in Hematology 11, pages 204062072096688.
Crossref
Crossref
Andreas H. Groll & Silke Gastine. 2020. Methods of Therapeutic Drug Monitoring Including Pharmacogenetics. Methods of Therapeutic Drug Monitoring Including Pharmacogenetics
185
224
.
Matthew O. Ruland, Tosha A. Egelund, John S. Ng, Scott M. Bradfield & Eric F. Egelund. (2019) Intravenous and Oral Posaconazole Pharmacokinetics in a Five-Year-Old With Mucor: A Case Report and Review of the Literature. The Journal of Pediatric Pharmacology and Therapeutics 24:6, pages 528-533.
Crossref
Crossref
Jingxiang Zhang, Liping Li, Quanzhen Lv, Lan Yan, Yan Wang & Yuanying Jiang. (2019) The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors. Frontiers in Microbiology 10.
Crossref
Crossref
Anne-Grete Märtson, Anette Veringa, Martijn Bakker, Edwin R. van den Heuvel, Daan J. Touw, Tjip S. van der Werf, Lambert F.R. Span & Jan-Willem C. Alffenaar. (2019) Posaconazole trough concentrations are not influenced by inflammation: A prospective study. International Journal of Antimicrobial Agents 53:3, pages 325-329.
Crossref
Crossref
Jonathan Spahr, Daniel J. Weiner, Dennis C. Stokes & Geoffrey Kurland. 2019. Kendig's Disorders of the Respiratory Tract in Children. Kendig's Disorders of the Respiratory Tract in Children
923
943.e7
.
Lijun Yang, Min Yang, Siying Li & Zhongxi Zhao. (2018) S-allylmercaptocysteine attenuates posaconazole-induced adverse effects in mice through antioxidation and anti-inflammation. International Immunopharmacology 58, pages 9-14.
Crossref
Crossref
Mar Tormo, Ariadna Pérez-Martínez, Marisa Calabuig, Juan Carlos Hernández-Boluda, Paula Amat, David Navarro & Carlos Solano. (2018) Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison. Mycoses 61:3, pages 206-212.
Crossref
Crossref
Whitley M. Yi, Kelly E. Schoeppler, Jaclyn Jaeger, Scott W. Mueller, Robert MacLaren, Douglas N. Fish & Tyree H. Kiser. (2017) Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Annals of Clinical Microbiology and Antimicrobials 16:1.
Crossref
Crossref
Romuald Bellmann & Piotr Smuszkiewicz. (2017) Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45:6, pages 737-779.
Crossref
Crossref
Sophie Berking, Daphne Doedens, Heidi Horns, Michael Fiegl, Helmut Ostermann & Christina T. Rieger. (2017) Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting. Mycoses 60:9, pages 600-606.
Crossref
Crossref
Michaela Döring, Karin Melanie Cabanillas Stanchi, Manon Queudeville, Judith Feucht, Franziska Blaeschke, Patrick Schlegel, Tobias Feuchtinger, Peter Lang, Ingo Müller, Rupert Handgretinger & Werner J. Heinz. (2017) Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology 143:7, pages 1281-1292.
Crossref
Crossref
E. Cendejas-Bueno, A. Forastiero, I. Ruiz, E. Mellado, J. Gavaldà & A. Gomez-Lopez. (2017) Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis. Diagnostic Microbiology and Infectious Disease 87:2, pages 112-117.
Crossref
Crossref
Shmuel Shoham, Andreas H. Groll, Vidmantas Petraitis & Thomas J. Walsh. 2017. Infectious Diseases. Infectious Diseases
1333
1344.e4
.
Wan Beom Park, Joo-Youn Cho, Sang-In Park, Eun Jung Kim, Seonghae Yoon, Seo Hyun Yoon, Jeong-Ok Lee, Youngil Koh, Kyoung-Ho Song, Pyoeng Gyun Choe, Kyung-Sang Yu, Eu suk Kim, Su Mi Bang, Nam Joong Kim, Inho Kim, Myoung-don Oh, Hong Bin Kim & Sang Hoon Song. (2016) Effectiveness of increasing the frequency of posaconazole syrup administration to achieve optimal plasma concentrations in patients with haematological malignancy. International Journal of Antimicrobial Agents 48:1, pages 106-110.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
883
884
.
Magali Bourdelin, Frédéric Grenouillet, Etienne Daguindau, Patrice Muret, Yohan Desbrosses, Jonathan Dubut, Eric Deconinck, Samuel Limat & Fabrice Larosa. (2014) Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice. Medical Mycology 52:7, pages 728-735.
Crossref
Crossref
Cecinati Valerio, Teresa Perillo, Letizia Brescia & Fabio Giovanni Russo. (2013) Antifungal Agents in Current Pediatric Practice. Current Infectious Disease Reports 15:3, pages 278-287.
Crossref
Crossref
Valerio Cecinati, Chiara Guastadisegni, Fabio Giovanni Russo & Letizia Pomponia Brescia. (2012) Antifungal therapy in children: an update. European Journal of Pediatrics 172:4, pages 437-446.
Crossref
Crossref
Alejandro Díaz & Carlos Garcés. (2012) Uso actual de los antifúngicos triazoles en niños. Infectio 16, pages 82-93.
Crossref
Crossref
Jonathan. Spahr, Daniel J. Weiner, Dennis C. Stokes & Geoffrey. Kurland. 2012. Kendig & Chernickâs Disorders of the Respiratory Tract in Children. Kendig & Chernickâs Disorders of the Respiratory Tract in Children
899
919
.
Andreas H. Groll & Dominik Schrey. (2010) The Current Role of Posaconazole in Managing Zygomycosis. Current Fungal Infection Reports 5:1, pages 29-33.
Crossref
Crossref
A.H. Groll & A. Tragiannidis. (2010) Update on antifungal agents for paediatric patients. Clinical Microbiology and Infection 16:9, pages 1343-1353.
Crossref
Crossref
S H Jang, P M Colangelo & J V S Gobburu. (2010) Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma. Clinical Pharmacology & Therapeutics 88:1, pages 115-119.
Crossref
Crossref
Yanjun Li, Ursula Theuretzbacher, Cornelius J. Clancy, M. Hong Nguyen & Hartmut Derendorf. (2010) Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. Clinical Pharmacokinetics 49:6, pages 379-396.
Crossref
Crossref
Lieven Meerpoel, Jan Heeres, Leo J. J. Backx, Louis J. E. Van der Veken, Rob Hendrickx, David Corens, Alex De Groot, Stef Leurs, Luc Van der Eycken, Johan Weerts, Paul Luyts, Frans Van Gerven, Filip A. A. Woestenborghs, Andre Van Breda, Michel Oris, Pascal van Dorsselaer, Gustaaf H. M. Willemsens, Danny Bellens, Patrick J. M. G. Marichal, Hugo F. Vanden Bossche & Frank C. Odds. (2010) Synthesis and in vitro and in vivo Antifungal Activity of the Hydroxy Metabolites of Saperconazole. ChemMedChem 5:5, pages 757-769.
Crossref
Crossref
Shmuel Shoham, Andreas H Groll & Thomas J Walsh. 2010. Infectious Diseases. Infectious Diseases
1477
1489
.
Gopal Krishna, A Moton, L Ma, M Martinho, M Seiberling & J McLeod. (2009) Effects of Oral Posaconazole on the Pharmacokinetics of Atazanavir Alone and With Ritonavir or With Efavirenz in Healthy Adult Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:4, pages 437-444.
Crossref
Crossref
S. Volkenstein, C. Unkel, A. Neumann, H. Sudhoff, H. Dermoumi, K. Jahnke & S. Dazert. (2007) Mucormykosen der NasennebenhöhlenMucormycosis in paranasal sinuses. HNO 57:8, pages 797-803.
Crossref
Crossref
Amy K. O'Sullivan, Ankur Pandya, George Papadopoulos, David Thompson, Amelia Langston, John Perfect & Milton C. Weinstein. (2009) Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value in Health 12:5, pages 666-673.
Crossref
Crossref
Eric J. Bow & D. Bacteriol. (2009) The role of second-generation triazole antifungal agents voriconazole and posaconazole in patients with hematologic malignancies. Current Fungal Infection Reports 3:1, pages 32-39.
Crossref
Crossref
Michele I. Morris. (2009) Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. American Journal of Health-System Pharmacy 66:3, pages 225-236.
Crossref
Crossref
Gopal Krishna, Allen Moton, Lei Ma, Ishani Savant, Monika Martinho, Michael Seiberling & James McLeod. (2009) Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers. Clinical Therapeutics 31:2, pages 286-298.
Crossref
Crossref
Andreas H. Groll, Emmanuel Roilides & Thomas J. Walsh. 2009. Clinical Mycology. Clinical Mycology
481
499
.
Andreas H. Groll & Thomas J. Walsh. 2009. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. Feigin and Cherry's Textbook of Pediatric Infectious Diseases
3271
3308
.
Andrew Y. Koh & Philip A. Pizzo. 2009. Oncology of Infancy and Childhood. Oncology of Infancy and Childhood
1099
1120
.
George R. ThompsonIIIIII & Thomas F. Patterson. 2010. Aspergillosis: From Diagnosis to Prevention. Aspergillosis: From Diagnosis to Prevention
230
262
.
M. M. Rodriguez, F. J. Pastor, C. Serena & J. Guarro. (2008) Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. Journal of Antimicrobial Chemotherapy 63:2, pages 361-364.
Crossref
Crossref
Javier Pemán & Benito Almirante. (2008) Avances en el diagnóstico y tratamiento de las infecciones por levaduras: papel de los nuevos antifúngicos. Enfermedades Infecciosas y Microbiología Clínica 26, pages 38-46.
Crossref
Crossref
Andreas H. Groll & Thomas Lehrnbecher. (2008) Posaconazole for paediatric patients: status of development and future perspectives. Mycoses 51:s2, pages 5-11.
Crossref
Crossref
Hans‐Peter Lipp. (2008) Antifungal agents – clinical pharmacokinetics and drug interactions. Mycoses 51:s1, pages 7-18.
Crossref
Crossref
Ranjan Chowdhry & William L. Marshall. (2008) Analytical Reviews: Antifungal Therapies in the Intensive Care Unit. Journal of Intensive Care Medicine 23:3, pages 151-158.
Crossref
Crossref
C. Garzoni & J. Garbino. (2008) New azoles as first line therapy for Paecilomyces lilacinus in transplant patients. Transplant Infectious Disease 10:2, pages 149-150.
Crossref
Crossref
Andreas H. Groll, Emmanuel Roilides & Thomas J. Walsh. (2008) Pediatric pharmacology of antifungal agents. Current Fungal Infection Reports 2:1, pages 49-56.
Crossref
Crossref
Carole A. SableKim M. Strohmaier & Jeffrey A. Chodakewitz. (2008) Advances in Antifungal Therapy. Annual Review of Medicine 59:1, pages 361-379.
Crossref
Crossref
Herbert Hof. (2008) Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?. Drug Resistance Updates 11:1-2, pages 25-31.
Crossref
Crossref
S. Bretagne. (2008) Posaconazole : un nouvel antifongique pour quelles indications ?. Antibiotiques 10:1, pages 42-49.
Crossref
Crossref
Andreas H. Groll & Thomas J. Walsh. 2008. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
316
335
.
Luis Ostrosky-Zeichner & John H. Rex. 2008. Critical Care Medicine. Critical Care Medicine
1089
1109
.
Stanley W. Chapman. (2008) Clinical trials report. Current Infectious Disease Reports 9:6, pages 445-447.
Crossref
Crossref
Eliane M. Billaud. (2007) Interactions métaboliques des antifongiques azolés. Journal de Mycologie Médicale 17:3, pages 168-176.
Crossref
Crossref
G. Sóczó, G. Kardos, P. M. McNicholas, E. Falusi, L. Gergely & L. Majoros. (2007) Posaconazole susceptibility testing against Candida species: comparison of broth microdilution and E-test methods. Mycoses 50:3, pages 178-182.
Crossref
Crossref
Peter H. Michelson, Rakesh Goyal & Geoffrey Kurland. (2007) Pulmonary complications of haematopoietic cell transplantation in children. Paediatric Respiratory Reviews 8:1, pages 46-61.
Crossref
Crossref
A. Paugam. (2007) Actualités sur le posaconazole. Médecine et Maladies Infectieuses 37:2, pages 71-76.
Crossref
Crossref
Oliver A. Cornely, Johan Maertens, Drew J. Winston, John Perfect, Andrew J. Ullmann, Thomas J. Walsh, David Helfgott, Jerzy Holowiecki, Dick Stockelberg, Yeow-Tee Goh, Mario Petrini, Cathy Hardalo, Ramachandran Suresh & David Angulo-Gonzalez. (2007) Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. New England Journal of Medicine 356:4, pages 348-359.
Crossref
Crossref
Andreas H. Groll & Thomas J. Walsh. 2007.
280
293
.
Andreas H. Groll, Julia Koehler & Thomas J. Walsh. 2007. Pediatric Infectious Diseases Revisited. Pediatric Infectious Diseases Revisited
405
472
.
Khaled H. Abu-Elteen & Mawieh M. Hamad. 2007. New Insights in Medical Mycology. New Insights in Medical Mycology
69
98
.
Andreas H. Groll & Thomas J. Walsh. (2006) Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 49:s1, pages 7-16.
Crossref
Crossref
H. Hof. (2006) A new, broad-spectrum azole antifungal: posaconazole ? mechanisms of action and resistance, spectrum of activity. Mycoses 49:s1, pages 2-6.
Crossref
Crossref
A.M. Bal. (2006) Importance of identification of zygomycetes in the era of newer antifungal agents. Transplant Infectious Disease 8:2, pages 122-123.
Crossref
Crossref
Harrys A Torres, Ray Y Hachem, Roy F Chemaly, Dimitrios P Kontoyiannis & Issam I Raad. (2005) Posaconazole: a broad-spectrum triazole antifungal. The Lancet Infectious Diseases 5:12, pages 775-785.
Crossref
Crossref